Underlying host risk factors for nontuberculous mycobacterial lung disease

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 1, 2013, Pages 110-123

  Chan, Edward D ^a,b,c   Iseman, Michael D ^b,c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

bronchiectasis; environmental mycobacteria; Marfan syndrome; nontuberculous mycobacteria; pectus excavatum; scoliosis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; FIBRILLIN 1; FIBRILLIN 2; GOLIMUMAB; INFLIXIMAB; RITUXIMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANKYLOSING SPONDYLITIS; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENTERITIS; GENE MUTATION; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LUNG ALVEOLUS PROTEINOSIS; LUNG DISEASE; LUNG SARCOIDOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM PEREGRINUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PNEUMOCONIOSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; RISK FACTOR;

ANIMALS; FEMALE; HUMANS; LUNG DISEASES; MALE; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; POSTMENOPAUSE; RISK FACTORS;

EID: 84874397842     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1333573     Document Type: Article

References (138)

1. Glassroth J. Pulmonary disease due to nontuberculous mycobacteria. Chest: 2008; 133 1 243 251
2. Okumura M., Iwai K., Ogata H., et al. Clinical factors on cavitary and nodular bronchiectatic types in pulmonary Mycobacterium avium complex disease. Intern Med: 2008; 47 16 1465 1472
3. Marras T. K., Daley C. L. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med: 2002; 23 3 553 567
4. Cassidy P. M., Hedberg K., Saulson A., McNelly E., Winthrop K. L. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis: 2009; 49 12 e124 e129
5. Griffith D. E., Stout J. E. It is better to light a candle.. than to repeat the opinions of experts. Am J Respir Crit Care Med: 2010; 182 7 865 866
6. Prevots D. R., Shaw P. A., Strickland D., et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med: 2010; 182 7 970 976
7. Winthrop K. L., McNelley E., Kendall B., et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med: 2010; 182 7 977 982
8. Iseman M. D., Marras T. K. The importance of nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med: 2008; 178 10 999 1000
9. van Ingen J., Hoefsloot W., Dekhuijzen P. N., Boeree M. J., van Soolingen D. The changing pattern of clinical Mycobacterium avium isolation in the Netherlands. Int J Tuberc Lung Dis: 2010; 14 9 1176 1180
10. Kasperbauer S. H., Daley C. L. Diagnosis and treatment of infections due to Mycobacterium avium complex. Semin Respir Crit Care Med: 2008; 29 5 569 576
11. Brown-Elliott B. A., Wallace R. J. Infections caused by nontuberculous mycobacteria. In: Mandell G. L., Bennett J. E., Dolin R., eds. Principles and Practice of Infectious Diseases. Philadelphia, PA Elsevier: 2005; 2909 2916
12. Koh W. J., Jeon K., Lee N. Y., et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med: 2011; 183 3 405 410
13. Marusić A., Katalinić-Janković V., Popović-Grle S., et al. Mycobacterium xenopi pulmonary disease-epidemiology and clinical features in non-immunocompromised patients. J Infect: 2009; 58 2 108 112
14. Doucette K., Fishman J. A. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis: 2004; 38 10 1428 1439 (Pubitemid 38678611)
15. Maimon N., Brunton J., Chan A. K., Marras T. K. Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept. Thorax: 2007; 62 8 739 740 (Pubitemid 47235021)
16. Marie I., Heliot P., Roussel F., Hervé F., Muir J. F., Levesque H. Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab. Rheumatology (Oxford): 2005; 44 9 1201 1202 (Pubitemid 41236037)
17. Marras T. K., Daley C. L. A systematic review of the clinical significance of pulmonary Mycobacterium kansasii isolates in HIV infection. J Acquir Immune Defic Syndr: 2004; 36 4 883 889 (Pubitemid 38944083)
18. Okubo H., Iwamoto M., Yoshio T., et al. Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infliximab. Mod Rheumatol: 2005; 15 1 62 64 (Pubitemid 40298426)
19. Smith M. B., Molina C. P., Schnadig V. J., Boyars M. C., Aronson J. F. Pathologic features of Mycobacterium kansasii infection in patients with acquired immunodeficiency syndrome. Arch Pathol Lab Med: 2003; 127 5 554 560 (Pubitemid 36534938)
20. van Ingen J., Boeree M., Janssen M., et al. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol: 2007; 3 7 414 419 (Pubitemid 47034543)
21. Chan E. D., Kaminska A. M., Gill W., et al. Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages. Scand J Infect Dis: 2007; 39 8 690 696 (Pubitemid 47189022)
22. Iseman M. D. The Theodore E. Woodward Award. Mycobacterium avium and slender women: an unrequited affair. Trans Am Clin Climatol Assoc: 1998; 109 199 202, discussion 203-204
23. Kim R. D., Greenberg D. E., Ehrmantraut M. E., et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med: 2008; 178 10 1066 1074
24. Tasaka S., Hasegawa N., Nishimura T., et al. Elevated serum adiponectin level in patients with Mycobacterium avium-intracellulare complex pulmonary disease. Respiration: 2010; 79 5 383 387
25. Tomii K., Iwata T., Oida K., et al. A probable case of adult Williams-Campbell syndrome incidentally detected by an episode of atypical mycobacterial infection [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi: 1989; 27 4 518 522 (Pubitemid 19169068)
26. Uji M., Matsushita H., Watanabe T., Suzumura T., Yamada M. A case of primary Sjögren's syndrome presenting with middle lobe syndrome complicated by nontuberculous mycobacteriosis [in Japanese]. Nihon Kokyuki Gakkai Zasshi: 2008; 46 1 55 59
27. Brownell I., Ramírez-Valle F., Sanchez M., Prystowsky S. Evidence for mycobacteria in sarcoidosis. Am J Respir Cell Mol Biol: 2011; 45 5 899 905
28. Noone P. G., Leigh M. W., Sannuti A., et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med: 2004; 169 4 459 467 (Pubitemid 38187117)
29. Chmura K., Chan E. D., Noone P. G., et al. A middle-aged woman with recurrent respiratory infections. Respiration: 2005; 72 4 427 430 (Pubitemid 41160179)
30. Lewis A. G. Jr, Dunbar F. P., Lasche E. M., et al. Chronic pulmonary disease due to atypical mycobacterial infections. Am Rev Respir Dis: 1959; 80 188 199
31. Jones V. F., Eid N. S., Franco S. M., Badgett J. T., Buchino J. J. Familial congenital bronchiectasis: Williams-Campbell syndrome. Pediatr Pulmonol: 1993; 16 4 263 267
32. George J., Jain R., Tariq S. M. CT bronchoscopy in the diagnosis of Williams-Campbell syndrome. Respirology: 2006; 11 1 117 119
33. Woodring J. H., Howard R. S. II, Rehm S. R. Congenital tracheobronchomegaly (Mounier-Kuhn syndrome): a report of 10 cases and review of the literature. J Thorac Imaging: 1991; 6 2 1 10
34. Abdallah E. G., Ashton R. W. Mounier-Kuhn syndrome: overcoming a lack of recognition. South Med J: 2008; 101 1 14 15
35. Christensen E. E., Dietz G. W., Ahn C. H., et al. Initial roentgenographic manifestations of pulmonary Mycobacterium tuberculosis, M. kansasii, and M. intracellularis infections. Chest: 1981; 80 2 132 136 (Pubitemid 11051783)
36. Rosenzweig D. Y. Pulmonary mycobacterial infections due to Mycobacterium intracellulare-avium complex: clinical features and course in 100 consecutive cases. Chest: 1979; 75 2 115 119 (Pubitemid 9128100)
37. Chan E. D., Iseman M. D. Potential association between calcified thoracic lymphadenopathy due to previous Histoplasma capsulatum infection and pulmonary Mycobacterium avium complex disease. South Med J: 1999; 92 6 572 576 (Pubitemid 29270186)
38. Andréjak C., Nielsen R., Thomsen V. O., Duhaut P., Sorensen H. T., Thomsen R. W. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax: 2012; Jul 10. [ Epub ahead of print]
39. Huang C-T, Tsai Y-J, Wu H-D., et al. Impact of non-tuberculous mycobacteria on pulmonary function decline in chronic obstructive pulmonary disease. Int J Tuberc Lung Dis: 2012; 16 4 539 545
40. Chan E. D., Feldman N. E., Chmura K., et al. Do mutations of the alpha-1-antitrypsin gene predispose to non-tuberculous mycobacterial infection? [abstract]. Am J Respir Crit Care Med: 2004; 169 A132
41. de Serres F. J. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest: 2002; 122 5 1818 1829 (Pubitemid 35366098)
42. Dahl M., Tybjaerg-Hansen A., Lange P., Vestbo J., Nordestgaard B. G. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann Intern Med: 2002; 136 4 270 279 (Pubitemid 34150756)
43. Shin M. S., Ho K-J. Bronchiectasis in patients with alpha 1-antitrypsin deficiency: a rare occurrence? Chest: 1993; 104 5 1384 1386 (Pubitemid 23327849)
44. Tomashefski J. F. Jr, Crystal R. G., Wiedemann H. P., Mascha E., Stoller J. K. Alpha 1-Antitrypsin Deficiency Registry Study Group The bronchopulmonary pathology of alpha-1 antitrypsin (AAT) deficiency: findings of the Death Review Committee of the national registry for individuals with Severe Deficiency of Alpha-1 Antitrypsin. Hum Pathol: 2004; 35 12 1452 1461 (Pubitemid 40017984)
45. Parr D. G., Guest P. G., Reynolds J. H., Dowson L. J., Stockley R. A. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med: 2007; 176 12 1215 1221 (Pubitemid 350256475)
46. Martínez-García M. A., Soler-Cataluña J. J., Donat Sanz Y., et al. Factors associated with bronchiectasis in patients with COPD. Chest: 2011; 140 5 1130 1137
47. Mulgrew A. T., Taggart C. C., Lawless M. W., et al. Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest: 2004; 125 5 1952 1957 (Pubitemid 38648435)
48. Cuvelier A., Muir J. F., Hellot M. F., et al. Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis. Chest: 2000; 117 2 415 419 (Pubitemid 30111592)
49. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest: 2000; 118 5 1480 1485
50. Cantin A. M., Woods D. E. Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection. Am J Respir Crit Care Med: 1999; 160 4 1130 1135 (Pubitemid 29487450)
51. Corbett E. L., Hay M., Churchyard G. J., et al. Mycobacterium kansasii and M. scrofulaceum isolates from HIV-negative South African gold miners: incidence, clinical significance and radiology. Int J Tuberc Lung Dis: 1999; 3 6 501 507 (Pubitemid 29260163)
52. Sonnenberg P., Murray J., Glynn J. R., Thomas R. G., Godfrey-Faussett P., Shearer S. Risk factors for pulmonary disease due to culture-positive M. tuberculosis or nontuberculous mycobacteria in South African gold miners. Eur Respir J: 2000; 15 2 291 296 (Pubitemid 30085955)
53. Kim Y. M., Kim M., Kim S. K., et al. Mycobacterial infections in coal workers' pneumoconiosis patients in South Korea. Scand J Infect Dis: 2009; 41 9 656 662
54. Chan E. D., King T. E. Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults. In: Flaherty K. R., ed. UpToDate. Waltham, MA UpToDate: 2013
55. Witty L. A., Tapson V. F., Piantadosi C. A. Isolation of mycobacteria in patients with pulmonary alveolar proteinosis. Medicine (Baltimore): 1994; 73 2 103 109 (Pubitemid 24114628)
56. Ramirez J., Savard E. V., Hawkins J. E. Biological effect of pulmonary washings from cases of alveolar proteinosis. Am Rev Respir Dis: 1966; 94 2 244 246
57. Abdul Rahman J. A., Moodley Y. P., Phillips M. J. Pulmonary alveolar proteinosis associated with psoriasis and complicated by mycobacterial infection: successful treatment with granulocyte-macrophage colony stimulating factor after a partial response to whole lung lavage. Respirology: 2004; 9 3 419 422 (Pubitemid 39382131)
58. Bakhos R., Gattuso P., Arcot C., Reddy V. B. Pulmonary alveolar proteinosis: an unusual association with Mycobacterium avium-intracellulare infection and lymphocytic interstitial pneumonia. South Med J: 1996; 89 8 801 802 (Pubitemid 26286683)
59. Bedrossian C. W., Luna M. A., Conklin R. H., Miller W. C. Alveolar proteinosis as a consequence of immunosuppression. A hypothesis based on clinical and pathologic observations. Hum Pathol: 1980; 11 5, Suppl 527 535
60. Carnovale R., Zornoza J., Goldman A. M., Luna M. Pulmonary alveolar proteinosis: its association with hematologic malignancy and lymphoma. Radiology: 1977; 122 2 303 306 (Pubitemid 8028933)
61. Goldschmidt N., Nusair S., Gural A., Amir G., Izhar U., Laxer U. Disseminated Mycobacterium kansasii infection with pulmonary alveolar proteinosis in a patient with chronic myelogenous leukemia. Am J Hematol: 2003; 74 3 221 223 (Pubitemid 37363028)
62. Prakash U. B., Barham S. S., Carpenter H. A., Dines D. E., Marsh H. M. Pulmonary alveolar phospholipoproteinosis: experience with 34 cases and a review. Mayo Clin Proc: 1987; 62 6 499 518 (Pubitemid 17084821)
63. Ramirez J. Pulmonary alveolar proteinosis. Treatment by massive bronchopulmonary lavage. Arch Intern Med: 1967; 119 2 147 156
64. Green D., Dighe P., Ali N. O., Katele G. V. Pulmonary alveolar proteinosis complicating chronic myelogenous leukemia. Cancer: 1980; 46 8 1763 1766 (Pubitemid 10011129)
65. Watanabe K., Sueishi K., Tanaka K., et al. Pulmonary alveolar proteinosis and disseminated atypical mycobacteriosis in a patient with busulfan lung. Acta Pathol Jpn: 1990; 40 1 63 66 (Pubitemid 20196849)
66. Wallis R. S., Schluger N. W. Pulmonary infectious complications of tumor necrosis factor blockade. Infect Dis Clin North Am: 2010; 24 3 681 692
67. Tubach F., Salmon D., Ravaud P., et al. Research Axed on Tolerance of Biotherapies Group Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum: 2009; 60 7 1884 1894
68. Wallis R. S. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum: 2008; 58 4 947 952 (Pubitemid 351563995)
69. Wallis R. S., Broder M., Wong J., Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis: 2004; 39 8 1254 1255 (Pubitemid 40169331)
70. Wallis R. S., Broder M. S., Wong J. Y., Hanson M. E., Beenhouwer D. O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis: 2004; 38 9 1261 1265 (Pubitemid 38608568)
71. Winthrop K., Baxter R., Liu L., et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis: 2013; 72 1 37 42
72. Gardam M. A., Keystone E. C., Menzies R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis: 2003; 3 3 148 155 (Pubitemid 36278124)
73. Salvana E. M., Cooper G. S., Salata R. A. Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients. J Infect: 2007; 55 6 484 487 (Pubitemid 350082471)
74. Winthrop K. L., Daley C. L., Griffith D. Nontuberuclous mycobacterial disease: updated diagnostic criteria for an under-recognized infectious complication of anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol: 2007; 3 10 E1
75. Keystone E., Heijde D., Mason D. Jr., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum: 2008; 58 11 3319 3329
76. Smolen J., Landewé R. B., Mease P., et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study: a randomised controlled trial. Ann Rheum Dis: 2009; 68 6 797 804
77. Bruns H., Meinken C., Schauenberg P., et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest: 2009; 119 5 1167 1177
78. Saliu O. Y., Sofer C., Stein D. S., Schwander S. K., Wallis R. S. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis: 2006; 194 4 486 492 (Pubitemid 44162660)
79. Bergstrom L., Yocum D. E., Ampel N. M., et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum: 2004; 50 6 1959 1966 (Pubitemid 38725108)
80. Mufti A. H., Toye B. W., Mckendry R. R., Angel J. B. Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use. Diagn Microbiol Infect Dis: 2005; 53 3 233 238 (Pubitemid 41607629)
81. Boulman N., Rozenbaum M., Slobodin G., Rosner I. Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis. Clin Exp Rheumatol: 2006; 24 6 723 (Pubitemid 46138811)
82. Winthrop K. L., Chang E., Yamashita S., Iademarco M. F., LoBue P. A. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis: 2009; 15 10 1556 1561
83. Winthrop K. L., Yamashita S., Beekmann S. E., Polgreen P. M. Infectious Diseases Society of America Emerging Infections Network Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis: 2008; 46 11 1738 1740 (Pubitemid 351706773)
84. Griffith D. E., Aksamit T., Brown-Elliott B. A., et al. ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med: 2007; 175 4 367 416
85. Bai X., Wilson S. E., Chmura K., Feldman N. E., Chan E. D. Morphometric analysis of Th(1) and Th(2) cytokine expression in human pulmonary tuberculosis. Tuberculosis (Edinb): 2004; 84 6 375 385 (Pubitemid 39451904)
86. Maglione P. J., Xu J., Chan J. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J Immunol: 2007; 178 11 7222 7234 (Pubitemid 46847448)
87. Lutt J. R., Pisculli M. L., Weinblatt M. E., Deodhar A., Winthrop K. L. Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. J Rheumatol: 2008; 35 8 1683 1685
88. Daley C. L., Griffith D. E. Pulmonary disease caused by rapidly growing mycobacteria. Clin Chest Med: 2002; 23 3 623 632, vii
89. Field S. K., Cowie R. L. Lung disease due to the more common nontuberculous mycobacteria. Chest: 2006; 129 6 1653 1672 (Pubitemid 43894999)
90. Griffith D. E., Girard W. M., Wallace R. J. Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an analysis of 154 patients. Am Rev Respir Dis: 1993; 147 5 1271 1278 (Pubitemid 23149890)
91. Iseman M. D., Buschman D. L., Ackerson L. M. Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex. Am Rev Respir Dis: 1991; 144 4 914 916
92. Prince D. S., Peterson D. D., Steiner R. M., et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med: 1989; 321 13 863 868 (Pubitemid 19238618)
93. Reich J. M., Johnson R. E. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern: the Lady Windermere syndrome. Chest: 1992; 101 6 1605 1609
94. Dhillon S. S., Watanakunakorn C. Lady Windermere syndrome: middle lobe bronchiectasis and Mycobacterium avium complex infection due to voluntary cough suppression. Clin Infect Dis: 2000; 30 3 572 575 (Pubitemid 30205306)
95. Chan E. D., Iseman M. D. Slender, older women appear to be more susceptible to nontuberculous mycobacterial lung disease. Gend Med: 2010; 7 1 5 18
96. Chalermskulrat W., Gilbey J. G., Donohue J. F. Nontuberculous mycobacteria in women, young and old. Clin Chest Med: 2002; 23 3 675 686
97. Tsuyuguchi K., Suzuki K., Matsumoto H., Tanaka E., Amitani R., Kuze F. Effect of oestrogen on Mycobacterium avium complex pulmonary infection in mice. Clin Exp Immunol: 2001; 123 3 428 434 (Pubitemid 32289962)
98. Hayashi M., Takayanagi N., Kanauchi T., Miyahara Y., Yanagisawa T., Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med: 2012; 185 5 575 583
99. Maffei M., Halaas J., Ravussin E., et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med: 1995; 1 11 1155 1161
100. Flier J. S. Lowered leptin slims immune response. Nat Med: 1998; 4 10 1124 1125 (Pubitemid 28468821)
101. Lord G. M., Matarese G., Howard J. K., Baker R. J., Bloom S. R., Lechler R. I. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature: 1998; 394 6696 897 901 (Pubitemid 28410912)
102. Matarese G., Moschos S., Mantzoros C. S. Leptin in immunology. J Immunol: 2005; 174 6 3137 3142 (Pubitemid 40354011)
103. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol: 2005; 115 5 911 919, quiz 920
104. Fantuzzi G., Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol: 2000; 68 4 437 446
105. Gainsford T., Willson T. A., Metcalf D., et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc Natl Acad Sci U S A: 1996; 93 25 14564 14568 (Pubitemid 26419007)
106. Mancuso P., Huffnagle G. B., Olszewski M. A., Phipps J., Peters-Golden M. Leptin corrects host defense defects after acute starvation in murine pneumococcal pneumonia. Am J Respir Crit Care Med: 2006; 173 2 212 218 (Pubitemid 43187894)
107. Moore S. I., Huffnagle G. B., Chen G-H, White E. S., Mancuso P. Leptin modulates neutrophil phagocytosis of Klebsiella pneumoniae. Infect Immun: 2003; 71 7 4182 4185 (Pubitemid 36753752)
108. Ordway D., Henao-Tamayo M., Smith E., et al. Animal model of Mycobacterium abscessus lung infection. J Leukoc Biol: 2008; 83 6 1502 1511 (Pubitemid 351960332)
109. Wieland C. W., Florquin S., Chan E. D., et al. Pulmonary Mycobacterium tuberculosis infection in leptin-deficient ob/ob mice. Int Immunol: 2005; 17 11 1399 1408 (Pubitemid 41631316)
110. Buyukoglan H., Gulmez I., Kelestimur F., et al. Leptin levels in various manifestations of pulmonary tuberculosis. Mediators Inflamm: 2007; 2007 64859
111. Schaible U. E., Kaufmann S. HE. Malnutrition and infection: complex mechanisms and global impacts. PLoS Med: 2007; 4 5 e115
112. van Crevel R., Karyadi E., Netea M. G., et al. Decreased plasma leptin concentrations in tuberculosis patients are associated with wasting and inflammation. J Clin Endocrinol Metab: 2002; 87 2 758 763 (Pubitemid 34158249)
113. Cakir B., Yönem A., Güler S., et al. Relation of leptin and tumor necrosis factor alpha to body weight changes in patients with pulmonary tuberculosis. Horm Res: 1999; 52 6 279 283 (Pubitemid 30463464)
114. Schwenk A., Hodgson L., Rayner C. F., Griffin G. E., Macallan D. C. Leptin and energy metabolism in pulmonary tuberculosis. Am J Clin Nutr: 2003; 77 2 392 398 (Pubitemid 36133382)
115. Faggioni R., Fantuzzi G., Fuller J., Dinarello C. A., Feingold K. R., Grunfeld C. IL-1 beta mediates leptin induction during inflammation. Am J Physiol: 1998; 274 1 Pt 2 R204 R208
116. Grunfeld C., Zhao C., Fuller J., et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest: 1996; 97 9 2152 2157
117. Sarraf P., Frederich R. C., Turner E. M., et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med: 1997; 185 1 171 175 (Pubitemid 27039451)
118. Carlson G. L., Saeed M., Little R. A., Irving M. H. Serum leptin concentrations and their relation to metabolic abnormalities in human sepsis. Am J Physiol: 1999; 276 4 Pt 1 E658 E662 (Pubitemid 29211337)
119. Yüksel I., Sencan M., Dökmetaş H. S., Dökmetaş I., Ataseven H., Yönem O. The relation between serum leptin levels and body fat mass in patients with active lung tuberculosis. Endocr Res: 2003; 29 3 257 264 (Pubitemid 37176585)
120. van Lettow M., van der Meer J. WM, West C. E., van Crevel R., Semba R. D. Interleukin-6 and human immunodeficiency virus load, but not plasma leptin concentration, predict anorexia and wasting in adults with pulmonary tuberculosis in Malawi. J Clin Endocrinol Metab: 2005; 90 8 4771 4776 (Pubitemid 41159370)
121. Settas L. D., Tsimirikas G., Vosvotekas G., Triantafyllidou E., Nicolaides P. Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra). J Clin Rheumatol: 2007; 13 4 219 220 (Pubitemid 47364586)
122. Denis M., Ghadirian E. Interleukin-1 is involved in mouse resistance to Mycobacterium avium. Infect Immun: 1994; 62 2 457 461 (Pubitemid 24033763)
123. Beamer G. L., Flaherty D. K., Assogba B. D., et al. Interleukin-10 promotes Mycobacterium tuberculosis disease progression in CBA/J mice. J Immunol: 2008; 181 8 5545 5550
124. Hickman S. P., Chan J., Salgame P. Mycobacterium tuberculosis induces differential cytokine production from dendritic cells and macrophages with divergent effects on naive T cell polarization. J Immunol: 2002; 168 9 4636 4642 (Pubitemid 34441370)
125. Guide S. V., Holland S. M. Host susceptibility factors in mycobacterial infection. Genetics and body morphotype. Infect Dis Clin North Am: 2002; 16 1 163 186 (Pubitemid 34234949)
126. Roesler H. The relation of the shape of the heart to the shape of the chest. Am J Radiol: 1934; 32 464 486
127. Davies M. K., Mackintosh P., Cayton R. M., Page A. J., Shiu M. F., Littler W. A. The straight back syndrome. Q J Med: 1980; 49 196 443 460 (Pubitemid 11210095)
128. Freed L. A., Levy D., Levine R. A., et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med: 1999; 341 1 1 7 (Pubitemid 29293713)
129. Roman M. J., Devereux R. B., Kramer-Fox R., Spitzer M. C. Comparison of cardiovascular and skeletal features of primary mitral valve prolapse and Marfan syndrome. Am J Cardiol: 1989; 63 5 317 321 (Pubitemid 19049242)
130. Judge D. P., Dietz H. C. Marfan's syndrome. Lancet: 2005; 366 9501 1965 1976 (Pubitemid 41713988)
131. Champsi J., Young L. S., Bermudez L. E. Production of TNF-alpha, IL-6 and TGF-beta, and expression of receptors for TNF-alpha and IL-6, during murine Mycobacterium avium infection. Immunology: 1995; 84 4 549 554
132. Denis M., Ghadirian E. Transforming growth factor beta (TGF-b1) plays a detrimental role in the progression of experimental Mycobacterium avium infection; in vivo and in vitro evidence. Microb Pathog: 1991; 11 5 367 372
133. Hirsch C. S., Yoneda T., Averill L., Ellner J. J., Toossi Z. Enhancement of intracellular growth of Mycobacterium tuberculosis in human monocytes by transforming growth factor-beta 1. J Infect Dis: 1994; 170 5 1229 1237 (Pubitemid 24328628)
134. Roberts T., Beyers N., Aguirre A., Walzl G. Immunosuppression during active tuberculosis is characterized by decreased interferon- gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor- beta, and interleukin-4 mRNA levels. J Infect Dis: 2007; 195 6 870 878 (Pubitemid 46363933)
135. Foster M. E., Foster D. R. Bronchiectasis and Marfan's syndrome. Postgrad Med J: 1980; 56 660 718 719 (Pubitemid 11197587)
136. Wood J. R., Bellamy D., Child A. H., Citron K. M. Pulmonary disease in patients with Marfan syndrome. Thorax: 1984; 39 10 780 784 (Pubitemid 14038832)
137. Paulson M. L., Olivier K. N., Holland S. M. Pulmonary non-tuberculous mycobacterial infection in congenital contractural arachnodactyly. Int J Tuberc Lung Dis: 2012; 16 4 561 563
138. Colombo R. E., Hill S. C., Claypool R. J., Holland S. M., Olivier K. N. Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest: 2010; 137 3 629 634